ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints

MT Newswires Live

04-25

ALX Oncology (ALXO) said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's (MRK) Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.

The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.

ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.

ALX Oncology shares were down more than 4% in recent Friday trading.

Price: 0.58, Change: -0.02, Percent Change: -3.49

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2530131735"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530131735\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2530131735?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-25 21:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530131735","market":"fut","top_or_hot":-1,"title":"ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints","media":"MT Newswires Live","content":"<html><body><p> ALX Oncology (ALXO) said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's (MRK) Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.</p><p>The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.</p><p>ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.</p><p>ALX Oncology shares were down more than 4% in recent Friday trading.</p><p>Price: 0.58, Change: -0.02, Percent Change: -3.49</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-25 21:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ALX Oncology (ALXO) said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's (MRK) Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.</p><p>The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.</p><p>ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.</p><p>ALX Oncology shares were down more than 4% in recent Friday trading.</p><p>Price: 0.58, Change: -0.02, Percent Change: -3.49</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2530131735","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530131735","pubTimestamp":1745589120,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ALX Oncology  said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's  Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.ALX Oncology shares were down more than 4% in recent Friday trading.Price: 0.58, Change: -0.02, Percent Change: -3.49","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"ALX Oncology的Evorpacept、Keytruda组合治疗头颈癌的2期试验未能达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALX":1,"ALXO":0.9,"MRK":1},"content_text":"ALX Oncology (ALXO) said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's (MRK) Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.ALX Oncology shares were down more than 4% in recent Friday trading.Price: 0.58, Change: -0.02, Percent Change: -3.49","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}